Enthralled with pipeline, GSK’s Witty targets £1B in annual cost cuts

By Ryan McBride In reaction to pricing pressure in Europe, GlaxoSmithKline ($GSK) aims to chop £1 billion ($1.57 billion) in annual spending in Europe, R&D and manufacturing ...

Analysis: Biogen’s $3.25B Tysabri pact leaves Elan hunting for deals

By John Carroll Biogen Idec’s ($BIIB) newly announced deal to acquire Elan’s 50% stake in Tysabri for $3.25 billion and a royalty stream ends an extended period of speculation ...

Elan seeks acquisitions after $3.25 billion MS drug deal

By Padraic Halpin (Reuters) – Irish drugmaker Elan is raising more than $3.25 billion by selling its interests in its main drug and will splash out most of the proceeds on acquisitions, ...

What Will Type 2 Diabetes Treatments Look Like in 5 Years?

By Sean Williams Times are changing in the biotech sector. No longer can companies simply sit on their FDA-approved drugs for years at a time, reaping the benefits from a decade or ...

EnteroMedics: Fat Zapper or Pulsing Placebo?

By Adam Feuerstein ST. PAUL, Minn. (TheStreet) –Into the obesity treatment fray rumbles EnteroMedics (ETRM_), which is developing a surgically implanted device that uses electrical ...

PhRMA Is Not Effective in Improving the Image of the Pharma Industry

By John LaMattina Those of you who regularly follow this blog know that I am big supporter of the biopharmaceutical industry. I spent 30 years in Pfizer’s R&D organization and ...

How Big Pharma Gets Bigger, And What Little Pharma Can Do About It

By Louis Dematteis With regulatory costs skyrocketing for biotech companies as FDA clinical trials continually become more onerous and expensive, it is the biggest companies with the ...

Avanir Pharmaceuticals Earnings: An Early Look

By Dan Caplinger Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors. The key to making smart investment decisions ...

Big Pharma’s Uphill 2013 Battle

By Maxx Chatsko Big pharma knew it faced an uphill battle when 2012 began. Even drug pipelines stocked full of potential couldn’t completely mitigate the patent cliff as several ...

Teva Pharmaceutical Earnings: An Early Look

By Dan Caplinger Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors. The key to making smart investment decisions ...

Illumina: Side Stepping Macro Pressure And Delivering In The Long Term

By Ivan Deryugin In the latter half of 2012, shares of Illumina (ILMN) saw increased volatility, owing to the twin combination of takeover speculation regarding Roche (RHHBY.OB), as ...

Merck KGaA signs $225 million personalised MS drug deal

By KEVIN GROGAN  Merck KGaA has signed a licensing deal for Opexa Therapeutics’ investigational T-cell therapy for multiple sclerosis. Tcelna (imilecleucel-T) is a potential ...
Page 1 of 5512345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS